Jeffrey Zhong discusses a retrospective UNITE consortium analysis of dose modifications of enfortumab vedotin plus pembrolizumab in 360 patients with advanced urothelial carcinoma ...
Susan Halabi presents a ctDNA-based prognostic model for radiographic progression-free survival in mCRPC patients receiving first-line androgen receptor pathway inhibitors. The mo ...
Pedro Barata discusses systemic therapy selection and monitoring in low-volume metachronous metastatic hormone-sensitive prostate cancer. He emphasizes that low disease volume doe ...
Indwelling urinary catheters (IUCs) are semi-rigid, flexible tubes. They drain the bladder but block the urethra. IUCshave double lumens, or separate channels, running down it lengthwise. One of the ...
Aurea Molina Diaz discusses the PrInCIS-NIADY, a nationwide Spanish real-world study of adjuvant nivolumab in patients with high-risk PD-L1-positive muscle-invasive urothelial carcinoma following ...
UTOPIA Phase 3 Trial of UGN-103 in Recurrent Low-Grade Intermediate-Risk NMIBC - Abhishek Srivastava
Abhishek Srivastava presents UTOPIA trial data, covering UGN-103, a reformulation of intravesical mitomycin reverse thermal hydrogel, in recurrent low-grade intermediate-risk non-muscle-invasive ...
Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...
(UroToday.com) The 2024 American Urological Association (AUA) Annual Meeting held in San Antonio, TX was host to a non-invasive bladder cancer moderated poster session. Dr. Bernard Bochner presented ...
ASCO 2025 Phase 1/2 Duravelo-1 study, nectin-4–targeting zelenectide pevedotin (BT8009), pembrolizumab, cisplatin-ineligible patients, locally advanced or metastatic urothelial cancer.
Development of a Risk Predictive Model for Erectile Dysfunction at 12 Months after COVID-19 Recovery: A Prospective Observational Study - Beyond the Abstract ...
(UroToday.com) The 2026 ASCO annual meeting featured a prostate cancer trials in progress session and a presentation by Dr. Oliver Sartor discussing AcTFirst, a phase 3 trial of 225 Ac-PSMA-617 + ...
AUA 2026, BCG naive and BCG-Exposed High-Risk Non–muscle Invasive Bladder Cancer, Intravesical MK-3120, anti–Nectin-4 monoclonal antibody, MK-3120 I-VESIC.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results